本頁面由Tiger Trade Technology Pte. Ltd.提供服務

再鼎醫藥

26.73
+1.094.23%
成交量:14.40萬
成交額:379.62萬
市值:30.03億
市盈率:-15.69
高:26.74
開:26.04
低:25.91
收:25.64
52周最高:34.72
52周最低:15.96
股本:1.12億
流通股本:9,711.04萬
量比:0.39
換手率:0.15%
股息:- -
股息率:- -
每股收益(TTM):-1.7030
每股收益(LYR):-1.6026
淨資產收益率:-26.91%
總資產收益率:-14.75%
市淨率:4.95
市盈率(LYR):-16.68

資料載入中...

2026/08/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/08/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/08/12

關聯方擬減持公告

Form 144 | Zai Lab Ltd董事 William Lis 計劃減持8506股,總價約$212650
2026/08/11

關聯方擬減持公告

Form 144 | Zai Lab Ltd 高管 Chen Yajing 擬減持619股,市值約15475美元
2026/08/06

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/08/06

重要事件披露

Form 8-K - Current report
2026/06/30

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/06/26

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/06/26

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/06/26

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/06/22

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/06/18

重要事件披露

Form 8-K - Current report
2026/06/11

超過5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/05/21

重要事件披露

Form 8-K - Current report
2026/05/18

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/05/15

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/05/14

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/05/14

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/05/13

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2026/05/07

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]